Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review

References

• Boolell V, Alamgeer M, David N, et al. The Evolution of Therapy in Non-Small Cell Lung Cancer. Cancer (Basel). 2015;7(3):1815–1846
   Google Scholar
• GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1260–134. https://doi.org/10.1016/S0140-6736(17)32130-X.
   Google Scholar
• Aguiar PN, Haaland B, Park W, et al. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer. JAMA Oncol. 2018;4(8):1080–1084.
   PubMed Web of Science ®Google Scholar
• Bertranou E, Bodnar C, Dansk V, et al. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M nonsmall cell lung cancer. J Med Econ. 2018;21(2):113–121.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, et al. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Oncologist. 2019;243(3):349–357.
   Google Scholar
• Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–548.
   PubMed Web of Science ®Google Scholar
• Travis D, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. JTO. 2011;6(2):244–285.
   Google Scholar
• Reck M, Rabe KF, Longo DL. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861.
   PubMed Web of Science ®Google Scholar
• Integraal Kankercentrum Nederland (IKNL). Non-small-cell lung cancer: Dutch guidelines [in Dutch]. 2015 ( 2018)
   Google Scholar
• Holleman MS, Al MJ, Zaim R, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ. 2020;21(1):153–164.
   PubMed Web of Science ®Google Scholar
• Wang A, Kubo J, Luo J, et al., ACtive and passive smoking in relation to lung cancer incidence in the women’s health initiative observational study prospeCtive cohort. Ann Oncol. 26(1): 221–230. 2015.
   PubMed Web of Science ®Google Scholar
• Ezeife DA, Kirk V, Chew DS, et al. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer. 2018;125:1–7.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q. Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. J Thorac Oncol. 2018;132(2):184–193.
   Google Scholar
• Cai H, Zhang L, Li N, et al. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China. Clin Ther. 2019;41(2):280–290.
   PubMed Web of Science ®Google Scholar
• Guan H, Liu G, Xie F, et al. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Clin Ther. 2019;41(11):2308–2320.
   PubMed Web of Science ®Google Scholar
• Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. J Comp Eff Res. 2019;8(11):853–863.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Dolatshahi Z, Mezginejad F, Nargesi S, et al. Cost-Effectiveness of endovascular aneurysm repair versus open surgical repair for ruptured abdominal aortic aneurysms: a systematic review. Iran J Radiol. 2021;18(3):e109932.
   Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. ISPOR health economic evaluation publication guidelines-CHEERS good reporting practices task force. consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Nargesi S, Rezapour A, Souresrafil A, et al. Cost-effectiveness analysis of pulse oximetry screening in the full-term neonates for diagnosis of congenital heart Disease: A systematic review. Iran J Pediatr. 2020;30:e105393.
   Web of Science ®Google Scholar
• World Bank, International Comparison Program database (2020) PPP conversion factor, GDP. World Bank Open Data. https://data.worldbank.org/indicator/PA.NUS.PPP. Accessed on 12 March 2020
   Google Scholar
• Nargesi S, Abutorabi A, Alipour V, et al., Cost-effectiveness of endovascular versus open repair of abdominal aortic aneurysm: A systematic review. Cardiovasc Drugs Ther. 35(4): 829–839. 2021.
   PubMed Web of Science ®Google Scholar
• Lasalvia P, Hernández F, Gil-Rojas Y, et al. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):821–827.
   PubMed Web of Science ®Google Scholar
• Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–390.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• National Healthcare Security AdministrationNotice on reimbursement decisions on including 17 cancer drugs in national reimbursement drug list by National Healthcare Security Administration. ( Available at:) http://www.gov.cn/xinwen/2018-10/10/content_5328891.htm Date accessed: October 10, 2018
   Google Scholar